Tiffny Chilampath
Payments from drug & device makers
Across 137 payments — averaging $18.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$695
- Amgen$410
- Exact Sciences$245
- Novo Nordisk$211
- AbbVie$140
- Pfizer$134
- plus $751 from 15 others
What the payments were for
- Food & beverage$2,587100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 48 | $695 |
| Amgen | 25 | $410 |
| Exact Sciences | 9 | $245 |
| Novo Nordisk | 10 | $211 |
| AbbVie | 8 | $140 |
| Pfizer | 6 | $134 |
| Astellas Pharma US Inc | 4 | $122 |
| Mallinckrodt Hospital Products Inc. | 3 | $78 |
| Boehringer Ingelheim | 3 | $73 |
| Esperion Therapeutics, Inc. | 3 | $68 |
| AstraZeneca | 4 | $67 |
| GSK | 3 | $64 |
| Sanofi-aventis U.S. LLC | 2 | $64 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $55 |
| Johnson & Johnson | 1 | $26 |
| Eisai Inc. | 1 | $25 |
| Abbott | 1 | $24 |
| Phadia US Inc. | 1 | $23 |
| Lundbeck LLC | 1 | $23 |
| Paratek Pharmaceuticals, Inc. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$125
How this compares
$2,587 in reported general payments places this provider in the 85th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 26 | $29,085 |
| EliquisApixaban | 21 | $22,920 |
| EntrestoSacubitril/Valsartan | 14 | $15,099 |
| JanuviaSitagliptin Phosphate | 14 | $9,671 |
| SynthroidLevothyroxine Sodium | 31 | $2,294 |
| Rosuvastatin Calcium | 149 | $1,728 |
| Gabapentin | 55 | $1,711 |
| Atorvastatin Calcium | 156 | $1,513 |
| Metoprolol Succinate | 72 | $1,296 |
| Levothyroxine Sodium | 101 | $1,162 |
| Losartan Potassium | 80 | $878 |
| Bupropion XlBupropion Hcl | 21 | $852 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 24 | $800 |
| Amlodipine Besylate | 113 | $761 |
| Escitalopram Oxalate | 67 | $725 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $73 | $29,08526 claims |
| PfizerEliquis | $134 | $22,92021 claims |
| AbbVieSynthroid | $140 | $2,29431 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 14,618 family providers in Florida.
Other family in Davie
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.